Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
NCT ID: NCT02603705
Last Updated: 2018-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
281 participants
INTERVENTIONAL
2016-03-07
2017-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain
NCT02716857
Bioequivalence Trial of a New Opioid Combination Compared to Reference
NCT00460785
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
NCT01081912
Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
NCT02367820
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions
NCT00857142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxycodone extended-release
Egalet abuse-deterrent, extended-release oxycodone tablet
Oxycodone extended-release
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxycodone extended-release
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has a clinical history of moderate-to-severe chronic noncancer pain ≥6 months.
* Has required opioid therapy for at least 14 days prior to Screening at a dose between 20 mg and 160 mg (inclusive) oxycodone/day (or opioid equivalent), and will, in the opinion of the investigator, continue to require opioid therapy (between 20 mg and 240 mg oxycodone/day, inclusive) for management of moderate-to-severe pain for the duration of the study.
* Has pain either not adequately controlled on current opioid regimen, requires a change of opioid due to tolerability of current opioid regimen or in the opinion of the investigator, would benefit from changing opioid for another reason.
* Has stable health, as determined by the investigator.
* If female, the patient is currently not pregnant, not breast-feeding, nor attempting to become pregnant (for 30 days before screening through the duration of the study), or is of non-childbearing potential.
* Other Criteria Apply
Exclusion Criteria
* Is receiving \>240 mg oxycodone daily (or opioid equivalent) within 30 days before Screening.
* Has a history of attempted suicide.
* Has used a spinal infusion pump within 6 months before Screening.
* Has clinically unstable cardiac disease (including atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia) and/or respiratory disease (including chronic obstructive pulmonary disease or sleep apnea).
* Has positive urine toxicity screen for drugs of abuse (with the exception of prescribed medications).
* Has positive result for tetrahydrocannabinol (even if legally prescribed).
* Has current (or history of within the last 12 months) drug dependence or substance abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision criteria (excluding nicotine).
* Other Criteria Apply
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Egalet Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 334
Huntsville, Alabama, United States
Site 328
Tucson, Arizona, United States
Site 332
Jacksonville, Florida, United States
Site 340
Miami Gardens, Florida, United States
Site 320
Plantation, Florida, United States
Site 302
Tampa, Florida, United States
Site 315
Tampa, Florida, United States
Site 310
Winter Haven, Florida, United States
Site 316
Dawsonville, Georgia, United States
Site 311
Marietta, Georgia, United States
Site 336
Bloomington, Illinois, United States
Site 345
Blue Island, Illinois, United States
Site 304
Evansville, Indiana, United States
Site 325
Valparaiso, Indiana, United States
Site 321
Overland Park, Kansas, United States
Site 342
Wichita, Kansas, United States
Site 329
New Orleans, Louisiana, United States
Site 326
Quincy, Massachusetts, United States
Site 303
St Louis, Missouri, United States
Site 306
Las Vegas, Nevada, United States
Site 313
Belvidere, New Jersey, United States
Site 346
Blackwood, New Jersey, United States
Site 323
Hartsdale, New York, United States
Site 338
Mooresville, North Carolina, United States
Site 333
Cincinnati, Ohio, United States
Site 343
Cleveland, Ohio, United States
Site 308
Huber Heights, Ohio, United States
Site 347
Kettering, Ohio, United States
Site 335
Oklahoma City, Oklahoma, United States
Site 312
Eugene, Oregon, United States
Site 322
Duncansville, Pennsylvania, United States
Site 324
Wyomissing, Pennsylvania, United States
Site 344
Myrtle Beach, South Carolina, United States
Site 314
Summerville, South Carolina, United States
Site 341
New Tazewell, Tennessee, United States
Site 318
Austin, Texas, United States
Site 330
Dallas, Texas, United States
Site 309
San Antonio, Texas, United States
Site 331
West Jordan, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OC-EG-303
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.